Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
NCT06383520

Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma

Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-05-14

100

Participants Needed

1

Research Sites

113 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a diagnostic study. Patients were recruited from patients with clinically suspected or confirmed hepatocellular carcinoma and healthy volunteers were recruited for PET/or PET/CT imaging targeting a GPC3-specific probe (in the case of 68Ga-NOTA-aGPC3-scFv) , to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET CT imaging in patients with contraindications. General Information, clinical data, blood routine, liver and renal function, and other imaging data were collected. The final diagnosis was based on the histopathology of biopsy or surgical specimens.

CONDITIONS

Official Title

Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma

Who Can Participate

Age: 18Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntarily participate and able to sign informed consent
  • Adults aged 18 to 65 years, any gender
  • Newly diagnosed or clinically suspected hepatocellular carcinoma with supporting imaging or histopathologic evidence
  • Healthy volunteers
  • Patients with a history of hepatocellular carcinoma, including remission or recurrence after treatment
  • Willing and able to follow scheduled visits, treatment plans, and laboratory tests
Not Eligible

You will not qualify if you...

  • Pregnant or lactating patients
  • Unable or unwilling to sign informed consent
  • Acute systemic diseases or electrolyte disorders
  • Known allergy to GPC3 imaging agents or their components
  • Fasting blood glucose over 11.0 mmol/L before 18F-FDG injection
  • Unable to complete PET/MR or PET/CT exams due to physical or psychological reasons
  • Poor compliance or other factors unfavorable for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

China, Hubei Province

Wuhan, Hubei, China, 430022

Actively Recruiting

Loading map...

Research Team

X

Xiaoli Lan, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here